Tumor classification is at the basis of accurate diagnosis and oncological decision-making, and primary evaluation includes the expression of Estrogen Receptor (ER), Progesterone Receptor (PR), and Human Epidermal Growth Factor Receptor 2 (HER2), which are indicative markers for hormonal and/or anti-HER2 therapies [2]. This evidence concerns the gene ERBB2 and neoplasm.